Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

77 projects found matching your search criteria :

  1. Targeted inhibition of STATs and IRFs as a novel treatment strategy in cardiovascular disease

    Call: OPUS 9 , Panel: NZ2

    Principal investigator: prof. Johannes Bluijssen (Bluyssen)

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii

  2. Aromatic aminotransferases from Candida albicans as molecular targets for antifungal chemotherapy.

    Call: OPUS 9 , Panel: NZ6

    Principal investigator: dr Iwona Gabriel

    Politechnika Gdańska, Wydział Chemiczny

  3. Optimisation of biocompatible scaffolds combinig graphen and defined stem cell populations for tissue regeneration.

    Call: SYMFONIA 3 , Panel: NZ4

    Principal investigator: prof. Ewa Zuba-Surma

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  4. Mechanisms underlying the targeting of coding sequence repeats by microRNA-like inhibitors

    Call: OPUS 8 , Panel: NZ1

    Principal investigator: dr Agnieszka Fiszer

    Instytut Chemii Bioorganicznej PAN

  5. Identification of new, clinically relevant genetic and epigenetic aberrations by next-generation sequencing in chronic m...

    Call: HARMONIA 6 , Panel: NZ5

    Principal investigator: dr Tomasz Stokłosa

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  6. Hydrogel microspheres containing dextran-based nanoparticles. Study on targeting effect in novel anticancer drug deliver...

    Call: PRELUDIUM 7 , Panel: NZ5

    Principal investigator: Aleksandra Kulikowska

    Politechnika Warszawska, Wydział Inżynierii Chemicznej i Procesowej

  7. Analysis of relations on the level of metabolome, miRNome, and transcriptome of human renal cancer: towards identificati...

    Call: OPUS 7 , Panel: NZ5

    Principal investigator: dr hab. Agnieszka Piekiełko-Witkowska

    Centrum Medyczne Kształcenia Podyplomowego

  8. Endogenny układ opioidowy i nocyceptynowy jako potencjalne cele farmakologiczne dla terapeutyków działających w układzie...

    Call: ETIUDA 2 , Panel: NZ7

    Principal investigator: dr Marta Zielińska

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  9. Mathematical modelling of pulse-wave propagation for cardiovascular diagnostics in patients on hemodialysis

    Call: OPUS 6 , Panel: ST7

    Principal investigator: prof. Jacek Waniewski

    Instytut Biocybernetyki i Inżynierii Biomedycznej im. Macieja Nałęcza PAN

  10. Targeted genomics of cardiovascular disease - multivariable genetic model of perioperative and long-term cardiovascular ...

    Call: OPUS 5 , Panel: NZ5

    Principal investigator: prof. Marek Sanak

    Uniwersytet Jagielloński – Collegium Medicum, Collegium Medicum, Wydział Lekarski

  11. Characteristics of the cell wall hydrolases of pathogenic bacteria Listeria monocytogenes and their partcipation in the ...

    Call: OPUS 5 , Panel: NZ6

    Principal investigator: dr hab. Magdalena Popowska

    Uniwersytet Warszawski, Wydział Biologii

  12. DNA double-stranded break repair proteins as a target for personalized cancer therapy based on synthetic lethality

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: dr hab. Tomasz Śliwiński

    Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

  13. PHARMACOTHERAPY OF OSTEOARTHRITIS: TRPV1 AND CB1 RECEPTORS AND THEIR ENDOGENOUS LIGANDS AS NEW TARGETS FOR PHARMACOLOGIC...

    Call: SONATA BIS 2 , Panel: NZ7

    Principal investigator: dr hab. Katarzyna Starowicz-Bubak

    Instytut Farmakologii PAN

  14. Identification of triple negative breast cancer with inactive DNA damage repair pathway by homologous recombination base...

    Call: SONATA 3 , Panel: NZ5

    Principal investigator: dr Paweł Domagała

    Pomorski Uniwersytet Medyczny w Szczecinie, Wydział Lekarski z Oddziałem Nauczania w Języku Angielskim

  15. Regulation of ALKBH proteins expression in cancer and its role in cancer therapy.

    Call: OPUS 2 , Panel: NZ4

    Principal investigator: prof. Elżbieta Grzesiuk

    Instytut Biochemii i Biofizyki PAN

  16. Targeting adenylate kinase 4 (AK4) as a new paradigm in the treatment of non-small cell lung cancer: discovery and evalu...

    Call: OPUS 26 , Panel: NZ7

    Principal investigator: dr Magdalena Wujak

    Uniwersytet Mikołaja Kopernika w Toruniu, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy

  17. Targeting IGH enhancer RNAs as a therapeutic approach in B-cell lymphoma

    Call: SONATA BIS 13 , Panel: NZ1

    Principal investigator: dr hab. Agnieszka Dzikiewicz-Krawczyk

    Instytut Genetyki Człowieka Polskiej Akademii Nauk

  18. Extensive analysis of the immunological profile of pediatric patients with acute lymphoblastic leukemia in order to iden...

    Call: PRELUDIUM 22 , Panel: NZ5

    Principal investigator: Anna Krętowska-Grunwald

    Uniwersytet Medyczny w Białymstoku

  19. Curdlan-based biomaterial as a nanostructure carrier for controlled and targeted drug delivery in the treatment of deep ...

    Call: PRELUDIUM 22 , Panel: NZ7

    Principal investigator: Aleksandra Nurzyńska

    Uniwersytet Medyczny w Lublinie

  20. Dissecting the regulatory interplay between proteases and protein kinases in acute lymphoblastic leukemia using mass cyt...

    Call: OPUS 24 , Panel: NZ5

    Principal investigator: dr hab. Marcin Poręba

    Politechnika Wrocławska

  21. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p...

    Call: PRELUDIUM BIS 4 , Panel: NZ7

    Principal investigator: prof. Tomasz Gośliński

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  22. Customized DNA-based nanocarriers to boost heart healing

    Call: M-ERA.NET 3 Call 2022 , Panel: NZ7

    Principal investigator: dr Monika Bzowska

    Uniwersytet Jagielloński

  23. Investigating the role of fibroblast growth factor receptors and STAT transcription factors in the targeted therapy of a...

    Call: PRELUDIUM BIS 4 , Panel: NZ5

    Principal investigator: prof. Ewa Marcinkowska

    Uniwersytet Wrocławski, Wydział Biotechnologii

  24. Modifiers of Muscleblind-like genes expression in health and disease.

    Call: SONATA BIS 12 , Panel: NZ5

    Principal investigator: dr hab. Ewa Stępniak-Konieczna

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii

  25. Targeting of metabolic and transcriptomic cross-talk between leukemic cells and macrophages as a therapeutic strategy in...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr Baran Natalia

    Instytut Hematologii i Transfuzjologii

  26. Mechanisms and consequences of CD19 loss in B-acute lymphoblastic leukaemia patients relapsing after CD19-CAR-T cell the...

    Call: PRELUDIUM BIS 3 , Panel: NZ5

    Principal investigator: prof. Przemysław Juszczyński

    Instytut Hematologii i Transfuzjologii

  27. Studies on the prevalence and properties of peptidoglycan peptidases as potential antimicrobial agents with targeted spe...

    Call: OPUS 22 , Panel: NZ6

    Principal investigator: dr hab. Benedykt Władyka

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  28. The role of NPM1 as biomarker of the targeted therapy efficacy in chronic lymphocytic leukemia patients

    Call: PRELUDIUM BIS 3 , Panel: NZ5

    Principal investigator: prof. Krzysztof Giannopoulos

    Uniwersytet Medyczny w Lublinie, Wydział Lekarski

  29. Role of RelA(p65) and cRel phosphorylations and their kinases in the biology of Diffuse-large B-cell lymphoma and Hodgki...

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr Maciej Szydłowski

    Instytut Hematologii i Transfuzjologii

  30. In the search of specific oxylipin fingerprint reflecting the development of endothelial dysfunction with the use of non...

    Call: SONATA 17 , Panel: NZ5

    Principal investigator: dr Agnieszka Kij

    Uniwersytet Jagielloński, Jagiellońskie Centrum Rozwoju Leków (JCET)

  31. New strategies in the treatment of non-small cell lung cancer based on silk nanocarriers targeting tumor vascularization

    Call: SONATA 17 , Panel: NZ7

    Principal investigator: dr Anna Florczak

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  32. Targeting of HSF1 as a therapeutic approach to inhibit the progression of hormone-dependent breast cancer.

    Call: OPUS 22 , Panel: NZ5

    Principal investigator: dr Natalia Vydra

    Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Oddział w Gliwicach

  33. Searching for new therapeutic targets in polyglutamine diseases

    Call: OPUS 22 , Panel: NZ2

    Principal investigator: dr hab. Marta Olejniczak

    Instytut Chemii Bioorganicznej Polskiej Akademii Nauk

  34. The biological role of sRNA OmrA and its impact on the level of virulence and adaptability of Yersinia enterocolitica en...

    Call: PRELUDIUM BIS 3 , Panel: NZ6

    Principal investigator: dr hab. Adrianna Raczkowska

    Uniwersytet Warszawski, Wydział Biologii

  35. Chronic pain in obesity: from cellular mechanisms to new strategies for targeted therapy.

    Call: SONATA 17 , Panel: NZ5

    Principal investigator: dr Anna Piotrowska-Murzyn

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  36. FGFR2-->JunB axis in progression of ER+ breast cancer - molecular analyses and prognostication

    Call: PRELUDIUM BIS 3 , Panel: NZ3

    Principal investigator: dr hab. Rafał Sądej

    Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  37. Combating addiction by targeting α3β4*-nicotinic acetylcholine receptors

    Call: OPUS 21 , Panel: NZ7

    Principal investigator: dr Ákos Nemecz

    Uniwersytet Mikołaja Kopernika w Toruniu, Wydział Nauk Biologicznych i Weterynaryjnych

  38. Mechanisms involved in heme acquisition - potential targets for therapies directed towards reduction of Porphyromonas gi...

    Call: OPUS 21 , Panel: NZ6

    Principal investigator: dr Michał Śmiga

    Uniwersytet Wrocławski, Wydział Biotechnologii

  39. Synthetic epidermal growth factor receptor inhibitor conjugated with nobel metal nanoparticles as a potential drug for t...

    Call: PRELUDIUM 20 , Panel: NZ7

    Principal investigator: Shaoshan Mai

    Gdański Uniwersytet Medyczny, Wydział Farmaceutyczny

  40. Molecular and cellular landscape of pulmonary and hepatic metastases of colorectal cancer with potential clinical implic...

    Call: PRELUDIUM 20 , Panel: NZ4

    Principal investigator: Marta Popęda

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  41. MicroRNAome maturation control and its application in selective targeting of cancer stem cells

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr Jakub Godlewski

    Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego Polskiej Akademii Nauk

  42. Identification of the interdependence between SWI/SNF-type chromatin remodeling complex, metabolism control and RNA modi...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr hab. Tomasz Sarnowski

    Instytut Biochemii i Biofizyki Polskiej Akademii Nauk

  43. Identification of surface proteins as alternate targets for CAR-T therapy against CD19-negative tumors.

    Call: PRELUDIUM BIS 2 , Panel: NZ6

    Principal investigator: dr hab. Magdalena Winiarska

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

  44. A novel approach based on the optimized multidrug combination for glioblastoma treatment.

    Call: SONATA 16 , Panel: NZ7

    Principal investigator: dr Małgorzata Kucińska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  45. The use of surface proteins to capture cancer cells with functionalized magnetic nanoparticles as an innovative theranos...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr hab. Joanna Dulińska-Litewka

    Uniwersytet Jagielloński, Collegium Medicum

  46. Identification of potential markers aiming early diagnostics of progression and tailoring metastasis-oriented therapies ...

    Call: OPUS 20 , Panel: NZ5

    Principal investigator: dr Natalia Bednarz-Knoll

    Gdański Uniwersytet Medyczny, Międzyuczelniany Wydział Biotechnologii Uniwersytetu Gdańskiego i Gdańskiego Uniwersytetu Medycznego

  47. Toxic RNA with expanded trinucleotide repeats: pathomechanism and therapeutic targets of neurological diseases

    Call: MAESTRO 12 , Panel: NZ3

    Principal investigator: prof. Krzysztof Sobczak

    Uniwersytet im. Adama Mickiewicza w Poznaniu, Wydział Biologii

  48. Modulation of immune cells activity in the tumor microenvironment by oligonucleotide therapeutics delivered by silk nano...

    Call: OPUS 19 , Panel: NZ6

    Principal investigator: dr hab. Hanna Dams-Kozłowska

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

  49. Atopic Dermatitis - searching for new strategic points of treatment, by evaluating clinical and prognostic significance ...

    Call: PRELUDIUM 19 , Panel: NZ5

    Principal investigator: Anna Zaryczańska

    Gdański Uniwersytet Medyczny, Wydział Lekarski

  50. New multifunctional drug-like ligands focusing on molecular targets associated with the symptoms and causes of Alzheimer...

    Call: PRELUDIUM 19 , Panel: NZ7

    Principal investigator: Anna Pasieka

    Uniwersytet Jagielloński, Collegium Medicum